3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
84
Breast Neoplasms
34
Colorectal Neoplasms
26
Lung Neoplasms
23
Rectal Neoplasms
22
Neoplasms
21
Esophageal Squamous Cell Carcinoma
20
Neoplasm Metastasis
19
Esophageal Neoplasms
19
Head and Neck Neoplasms
17
Stomach Neoplasms
15
Pancreatic Neoplasms
15
Squamous Cell Carcinoma of Head and Neck
14
Triple Negative Breast Neoplasms
12
Small Cell Lung Carcinoma
12
Ovarian Neoplasms
11
Recurrence
10
Nasopharyngeal Carcinoma
10
Carcinoma, Squamous Cell
10
Uterine Cervical Neoplasms
9
Leukemia, Myeloid, Acute
9
Colonic Neoplasms
9
Glioblastoma
8
Prostatic Neoplasms
7
Lymphoma, Large B-Cell, Diffuse
7
Lymphoma
7
Sarcoma
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
6
Melanoma
6
Lymphoma, Non-Hodgkin
6
Interventions
Everolimus
9
Cisplatin
8
Temozolomide
6
Nivolumab
5
Etoposide
5
Carboplatin
5
Bevacizumab
5
lutetium Lu 177 dotatate
4
Capecitabine
4
pembrolizumab
3
Irinotecan
3
sintilimab
2
dostarlimab
2
cabozantinib
2
azaspirane
2
avelumab
2
atezolizumab
2
Paclitaxel
2
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
2
Ipilimumab
2
Immunoglobulin G
2
IFL protocol
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Disulfides
2
zimberelimab
1
surufatinib
1
selinexor
1
pertuzumab
1
pasireotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Carcinoma, Neuroendocrine
×
Drug Therapy
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled